Dyadic International (DYAI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
12 May, 2026Executive summary
The 2026 Annual Meeting will be held virtually on June 18, 2026, with shareholders voting on key proposals including director election, a reverse stock split, auditor ratification, and executive compensation approval.
Shareholders of record as of April 24, 2026, are eligible to vote, with multiple voting methods available including internet, phone, mail, and during the virtual meeting.
Forward-looking statements highlight risks related to Nasdaq compliance, financial performance, and market conditions.
Voting matters and shareholder proposals
Proposals include electing one Class I director for a term ending in 2029, authorizing a reverse stock split (2:1 to 10:1), ratifying Crowe LLP as auditor for 2026, and an advisory vote on executive compensation.
The Board recommends voting FOR all proposals.
Shareholder proposals for the 2027 meeting must be submitted by January 12, 2027, with specific advance notice requirements.
Board of directors and corporate governance
The Board consists of four members, with a classified structure and separation of Chairman and CEO roles.
All directors attended at least 75% of meetings in 2025.
Committees include Audit, Compensation, and Nominating, each with defined charters and independent members.
The Nominating Committee considers a broad range of qualifications for director candidates and accepts shareholder recommendations.
A Code of Conduct and Ethics applies to all directors, officers, and employees.
Latest events from Dyadic International
- All proposals passed, with strategic focus on commercial growth and Nasdaq compliance efforts.DYAI
AGM 202618 Jun 2026 - Facing potential Nasdaq delisting for bid price and equity deficiencies, with a hearing planned.DYAI
Proxy filing18 Jun 2026 - Commercial stage reached with six product launches, global distribution, and early recurring revenues.DYAI
Lytham Partners Spring 2026 Investor Conference28 May 2026 - Commercializing animal-free proteins with scalable platforms and recurring revenues across key markets.DYAI
Sidoti Micro-Cap Virtual Conference20 May 2026 - Commercial-stage protein innovator drives growth with animal-free products and global partnerships.DYAI
Investor presentation20 May 2026 - Q1 2026 revenue rose 182% to $1.11M, with net loss narrowing and global expansion underway.DYAI
Q1 202619 May 2026 - C1 platform delivers rapid, high-yield, animal-free biologics with proven safety and global validation.DYAI
Investor presentation1 May 2026 - Virtual meeting to vote on director, reverse split, auditor, and executive pay; board urges approval.DYAI
Proxy filing1 May 2026 - Net loss widened to $7.36M on lower revenue, with expanded commercialization and partnerships.DYAI
Q4 202525 Mar 2026